Cimerli Purple Book BLA 761165

BLA number
761165
Proprietary names
Cimerli
Proper names
ranibizumab-eqrn
Applicant
Sandoz Inc.
Center
CDER
First observed release
2022-07-01
Latest observed release
2026-06-01
Newest archive release
2026-06-01
FDA patent list
No patents listed in the captured FDA patent list; source updated 2025-06-11
Coverage
Present in newest release

Latest Known Product Presentations#

Product, Proprietary name, Proper name table
ProductProprietary nameProper nameLicense typeStrengthDosage formRoutePresentationMarketingLicensureApprovalPatent list provided
001Cimerliranibizumab-eqrn351(k) Interchangeable10MG/ML (0.5MG/0.05ML)InjectionIntravitrealSingle-Dose VialRxLicensed2022-08-02
002Cimerliranibizumab-eqrn351(k) Interchangeable6MG/ML (0.3MG/0.05ML)InjectionIntravitrealSingle-Dose VialRxLicensed2022-08-02

Reference Biological Product#

BLA, Proprietary name, Proper name table
BLAProprietary nameProper nameLicense typeStatusLatest source
125156Lucentisranibizumab351(a)Disc*2026-06-01

Published Patent List#

No patents for this BLA were listed in the FDA Purple Book patent list captured from the source updated 2025-06-11.

Official Monthly Change Events#

Release, Event, Product table
ReleaseEventProductNameLicense typeStatusApplicant
2024-07-01U001Cimerli351(k) InterchangeableRxSandoz Inc.
2024-07-01U002Cimerli351(k) InterchangeableRxSandoz Inc.
2023-05-01U001Cimerli351(k) InterchangeableRxCoherus BioSciences, Inc.
2023-05-01U002Cimerli351(k) InterchangeableRxCoherus BioSciences, Inc.
2022-07-01N001Cimerli351(k) InterchangeableRxCoherus BioSciences, Inc.
2022-07-01N002Cimerli351(k) InterchangeableRxCoherus BioSciences, Inc.

Observed Product State History#

Release, Product, Name table
ReleaseProductNameLicense typeMarketingLicensureApproval
2022-07-01001Cimerli351(k) InterchangeableRxLicensed2022-08-02
2022-07-01002Cimerli351(k) InterchangeableRxLicensed2022-08-02